LMT vs PPCB · P/E 20, rev $75.05B vs P/E 0.0, $3.9M cap
Lockheed Martin Corporation (LMT) versus Propanc Biopharma, Inc. Common Stock (PPCB) — a side-by-side from cached financials, not a winner call.
Lockheed Martin Corporation (LMT) is a aerospace & defense company listed on US. It is led by Jim Taiclet.
Propanc Biopharma, Inc. Common Stock (PPCB) is a biotechnology company listed on NASDAQ.
Latest reported LMT revenue for 2025-12-31 was $75.05B. Net income was $5.02B. Revenue was up 5.6% from 2024-12-31 to 2025-12-31. LMT currently screens at market cap $108.37B and trailing P/E 19.9.
PPCB does not have a complete income-statement cache yet.
LMT currently screens at market cap $108.37B and trailing P/E 19.9. PPCB currently screens at market cap $3.9M and trailing P/E 0.0.
Not investment advice. Open the LMT and PPCB stock pages for the full models.
Not investment advice.